Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 11:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,871 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Carbohydrate Control Clear all
Completed Not applicable Interventional Results available

Direct Peritoneal Resuscitation Effects in the Damage Control Patient

NCT01771055
View directory record Official record
Conditions
Traumatic Injury
Interventions
Galactose, Standard surgical methods
Procedure
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 27, 2026, 11:14 PM EDT
Terminated Phase 2 Interventional

Cognitive REmediation After Trauma Exposure Trial = CREATE Trial

NCT01416948
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions
Methylphenidate Hydrochloride 20 mg, Placebo Capsule, Galantamine 12 mg
Drug
Lead sponsor
INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
San Diego, California • Boston, Massachusetts • Manchester, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2013 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Lansoprazole in Chronic Post Nasal Drip

NCT00335283
View directory record Official record
Conditions
Larynx Disease
Interventions
Lansoprazole Tablet, PH and impedence testing, manometry, lansoprazole, placebo
Drug · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

To Investigate the Effect of Arabinogalactan on the Gut Microbiome in Adults

NCT04351841
View directory record Official record
Conditions
Gut Microbiota
Interventions
arabinogalactan, maltodextrin
Other
Lead sponsor
Biofortis, Merieux NutriSciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Not applicable Interventional

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia

NCT00002042
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Epoetin alfa
Drug
Lead sponsor
Ortho Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Not applicable Interventional

Safety and Feasibility of a Low Carbohydrate Diet in Children With Type 1 Diabetes

NCT04228822
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Low carbohydrate diet
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
5 Years to 11 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 27, 2026, 11:14 PM EDT
Terminated Phase 3 Interventional

Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma

NCT00198315
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Medpulser electroporation with Bleomycin, Tumor surgical excision
Combination Product · Procedure
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Phase 2 Interventional Results available

Study of CB-183,315 in Participants With Clostridium Difficile Infection

NCT01085591
View directory record Official record
Conditions
Clostridium Difficile Infection, Diarrhea
Interventions
CB-183,315, Placebo, Vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Washington D.C., District of Columbia • Saint Cloud, Florida • Decatur, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 27, 2026, 11:14 PM EDT
Not listed Phase 4 Interventional

Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome

NCT01170338
View directory record Official record
Conditions
Smoking, Acute Coronary Syndrome
Interventions
Varenicline 100 mg by mouth twice daily, control
Drug
Lead sponsor
Newark Beth Israel Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 27, 2010 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Effect of Tablet Size on Cognitive Performance Caffeine

NCT03694886
View directory record Official record
Conditions
Placebo Effect
Interventions
Caffeine Anhydrous with small sucrose pill, Placebo - large sucrose pill, Caffeine Anhydrous with large sucrose pill, Placebo - small sucrose pill
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Not applicable Interventional Results available

ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)

NCT03651622
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Overweight and Obesity
Interventions
Hypocaloric, low carbohydrate diet, Hypocaloric, moderate low fat diet, Mediterranean diet, no caloric restriction
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
19 Years to 30 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Palo Alto, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Peanuts and Glycemic Control

NCT03654651
View directory record Official record
Conditions
Type2 Diabetes, Cardiovascular Diseases
Interventions
Peanut, High carbohydrate snack
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Not applicable Interventional Results available

IV Insulin Protocol in Diabetes and Renal Transplantation

NCT00609986
View directory record Official record
Conditions
Kidney Transplantation, Diabetes, Hyperglycemia
Interventions
insulin, NPH Insulin or glargine insulin and aspartame insulin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2013 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Primary Care Beverage Study

NCT02257203
View directory record Official record
Conditions
Obesity, Dental Caries
Interventions
Sugar Sweetened Beverage Education, Reading Education
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex

NCT05794503
View directory record Official record
Conditions
Urinary Retention Postoperative, Laparoscopic Cholecystectomy, Neuromuscular Blockade, Sugammadex, Neostigmine, Neuromuscular Blocking Agents, Physiological Effects of Drugs
Interventions
Neostigmine, Sugammadex
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

NCT01809327
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encinitas, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 27, 2026, 11:14 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effects of Lactoferrin-enriched Whey on Iron Status in Females

NCT06232642
View directory record Official record
Conditions
Serum Ferritin
Interventions
Lactoferrin, iron and B12 in Whey Protein, Lactoferrin, Iron and B12 in Rice Protein, Lactoferrin, Iron and B12 in Maltrodextrin
Dietary Supplement
Lead sponsor
Utah State University
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Logan, Utah
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off

NCT01283594
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Tozadenant (SYN115) 60 mg BID, Placebo, Levodopa (L-dopa), Tozadenant (SYN115) 120 mg BID, Tozadenant (SYN115) 180 mg BID, Tozadenant (SYN115) 240 mg BID
Drug
Lead sponsor
Biotie Therapies Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
40
States / cities
Birmingham, Alabama • La Jolla, California • Loma Linda, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Not applicable Interventional

Full Day and Night Closed-Loop With DiAs Platform

NCT02147860
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Diabetes Assistant (DiAs) with USS Virginia, Sensor Augmented Pump Therapy
Device · Other
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 35 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Stanford, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Dietary Fiber on Gastrointestinal Function

NCT01495182
View directory record Official record
Conditions
Gastrointestinal Health
Interventions
Dietary fiber
Other
Lead sponsor
Ingredion Incorporated
Industry
Eligibility
18 Years to 54 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Glen Ellyn, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 27, 2026, 11:14 PM EDT
Withdrawn Phase 1 Interventional

Thiamine Supplementation in Patients With Septic Shock

NCT03122678
View directory record Official record
Conditions
Septic Shock, Shock, Septic, Lactic Acidosis, Thiamine Deficiency
Interventions
Thiamine, Placebos
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Not applicable Interventional Results available

Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease

NCT03058679
View directory record Official record
Conditions
Crohn Disease
Interventions
Diet
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
35
States / cities
Tucson, Arizona • San Francisco, California • Denver, Colorado + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 27, 2026, 11:14 PM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

NCT03351608
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 16 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 27, 2026, 11:14 PM EDT
Recruiting Phase 2 Interventional

Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye

NCT07413172
View directory record Official record
Conditions
Dry Eye, Eye Diseases, Eyes Dry Chronic
Interventions
Autologous Serum Tears (50% Autologous Serum Tears + 0.2% Sodium Hyaluronate), Biological - Autologous Serum Tears (50% Autologous Serum Tears + Balanced Saline Solution (BSS), Standard of Care (SOC) Treatment
Biological · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 27, 2026, 11:14 PM EDT